{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:03:20Z","timestamp":1794024200425,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["T2019-011"],"award-info":[{"award-number":["T2019-011"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-9AU"],"award-info":[{"award-number":["CA209-9AU"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA196521"],"award-info":[{"award-number":["P30 CA196521"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA224319"],"award-info":[{"award-number":["U24CA224319"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation for the National Institutes of Health (FNIH)\/Partnership for Accelerating Cancer Therapies","id":[{"id":"https:\/\/ror.org\/00k86s890","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-altering. We initiated a phase 2 study in which patients with MIBC received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients achieving a clinical complete response (cCR) could proceed without cystectomy. The co-primary objectives were to assess the cCR rate and the positive predictive value of cCR for a composite outcome: 2-year metastasis-free survival in patients forgoing immediate cystectomy or &lt;ypT1N0 in patients electing immediate cystectomy. Seventy-six patients were enrolled; of these, 33 achieved a cCR (43%, 95% confidence interval (CI): 32%, 55%), and 32 of 33 who achieved a cCR opted to forgo immediate cystectomy. The positive predictive value of cCR was 0.97 (95% CI: 0.91, 1), meeting the co-primary objective. The most common adverse events were fatigue, anemia, neutropenia and nausea. Somatic alterations in pre-specified genes (\n                    <jats:italic>ATM<\/jats:italic>\n                    ,\n                    <jats:italic>RB1<\/jats:italic>\n                    ,\n                    <jats:italic>FANCC<\/jats:italic>\n                    and\n                    <jats:italic>ERCC2<\/jats:italic>\n                    ) or increased tumor mutational burden did not improve the positive predictive value of cCR. Exploratory analyses of peripheral blood mass cytometry and soluble protein analytes demonstrated an association between the baseline and on-treatment immune contexture with clinical outcomes. Stringently defined cCR after gemcitabine, cisplatin, plus nivolumab facilitated bladder sparing and warrants further study. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03558087\">NCT03558087<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02568-1","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T12:02:13Z","timestamp":1696248133000},"page":"2825-2834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-9378","authenticated-orcid":false,"given":"Matthew D.","family":"Galsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8948-5689","authenticated-orcid":false,"given":"Sudeh","family":"Izadmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6948-0626","authenticated-orcid":false,"given":"Edgar","family":"Gonzalez-Kozlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6041-1344","authenticated-orcid":false,"given":"Kevin G.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam El","family":"Achkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya B.","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Paul","family":"Cetnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock O.","family":"Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anishka","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-7405","authenticated-orcid":false,"given":"Christos","family":"Kyriakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomi","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-2078","authenticated-orcid":false,"given":"Mahalya","family":"Gogerly-Moragoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Nose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Del Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kenneth","family":"Haines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6860-2401","authenticated-orcid":false,"given":"Robert M.","family":"Samstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-4187","authenticated-orcid":false,"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menggang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Kim-Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-2426","authenticated-orcid":false,"given":"Robert","family":"Sebra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0834-8178","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-9520","authenticated-orcid":false,"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":false,"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"2568_CR1","doi-asserted-by":"publisher","first-page":"pky075","DOI":"10.1093\/jncics\/pky075","volume":"2","author":"KE Marqueen","year":"2018","unstructured":"Marqueen, K. E. et al. Early mortality in patients with muscle-invasive bladder cancer undergoing cystectomy in the United States. JNCI Cancer Spectr. 2, pky075 (2018).","journal-title":"JNCI Cancer Spectr."},{"key":"2568_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859\u2013866 (2003).","journal-title":"N. Engl. J. Med."},{"key":"2568_CR3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"G Griffiths","year":"2011","unstructured":"Griffiths, G., Hall, R., Sylvester, R., Raghavan, D. & Parmar, M. K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171\u20132177 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2568_CR4","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","volume":"27","author":"TW Flaig","year":"2021","unstructured":"Flaig, T. W. et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin. Cancer Res. 27, 2435\u20132441 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2568_CR5","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1200\/JCO.1998.16.4.1298","volume":"16","author":"HW Herr","year":"1998","unstructured":"Herr, H. W., Bajorin, D. F. & Scher, H. I. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J. Clin. Oncol. 16, 1298\u2013301 (1998).","journal-title":"J. Clin. Oncol."},{"key":"2568_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3233\/BLC-170134","volume":"3","author":"GW Moran","year":"2017","unstructured":"Moran, G. W. et al. Systematic review and meta-analysis on the efficacy of chemotherapy with transurethral resection of bladder tumors as definitive therapy for muscle invasive bladder cancer. Bladder Cancer 3, 245\u2013258 (2017).","journal-title":"Bladder Cancer"},{"key":"2568_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.juro.2014.03.078","volume":"192","author":"A Meyer","year":"2014","unstructured":"Meyer, A. et al. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder. J. Urol. 192, 696\u2013701 (2014).","journal-title":"J. Urol."},{"key":"2568_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.eururo.2008.08.027","volume":"55","author":"E Solsona","year":"2009","unstructured":"Solsona, E. et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur. Urol. 55, 911\u2013921 (2009).","journal-title":"Eur. Urol."},{"key":"2568_CR9","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.juro.2009.01.115","volume":"181","author":"RW deVere White","year":"2009","unstructured":"deVere White, R. W. et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J. Urol. 181, 2476\u20132480; discussion 2480\u20132481 (2009).","journal-title":"J. Urol."},{"key":"2568_CR10","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353\u20133360 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2568_CR11","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714 (2019).","journal-title":"Nat. Med."},{"key":"2568_CR12","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","volume":"20","author":"AR de Biasi","year":"2014","unstructured":"de Biasi, A. R., Villena-Vargas, J. & Adusumilli, P. S. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. 20, 5384\u20135391 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2568_CR13","doi-asserted-by":"crossref","unstructured":"Gupta, S. et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J. Clin. Oncol. 38, 439\u2013439 (2020).","DOI":"10.1200\/JCO.2020.38.6_suppl.439"},{"key":"2568_CR14","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.21.01003","volume":"39","author":"TL Rose","year":"2021","unstructured":"Rose, T. L. et al. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J. Clin. Oncol. 39, 3140\u20133148 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2568_CR15","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","volume":"36","author":"G Iyer","year":"2018","unstructured":"Iyer, G. et al. Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J. Clin. Oncol. 36, 1949\u20131956 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2568_CR16","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140\u20131153 (2014).","journal-title":"Cancer Discov."},{"key":"2568_CR17","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","volume":"2","author":"D Liu","year":"2016","unstructured":"Liu, D. et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2, 1094\u20131096 (2016).","journal-title":"JAMA Oncol."},{"key":"2568_CR18","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","volume":"68","author":"ER Plimack","year":"2015","unstructured":"Plimack, E. R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959\u2013967 (2015).","journal-title":"Eur. Urol."},{"key":"2568_CR19","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1200\/JCO.2022.40.16_suppl.4522","volume":"40","author":"G Iyer","year":"2022","unstructured":"Iyer, G. et al. Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314. J. Clin. Oncol. 40, 4522 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2568_CR20","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2022.40.16_suppl.4581","volume":"40","author":"ER Plimack","year":"2022","unstructured":"Plimack, E. R. et al. S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation. J. Clin. Oncol. 40, 4581 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2568_CR21","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo, M. Y. et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 36, 1685\u20131694 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2568_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.eururo.2017.12.001","volume":"73","author":"MD Galsky","year":"2017","unstructured":"Galsky, M. D. et al. Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes. Eur. Urol. 73, 751\u2013759 (2017).","journal-title":"Eur. Urol."},{"key":"2568_CR23","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha, D. et al. Tumor mutational burden (TMB) as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808 (2020).","journal-title":"Cancer Discov."},{"key":"2568_CR24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."},{"key":"2568_CR25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","volume":"74","author":"V Panebianco","year":"2018","unstructured":"Panebianco, V. et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur. Urol. 74, 294\u2013306 (2018).","journal-title":"Eur. Urol."},{"key":"2568_CR26","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James, N. D. et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N. Engl. J. Med. 366, 1477\u20131488 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2568_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2019.11.001","volume":"77","author":"RA Huddart","year":"2020","unstructured":"Huddart, R. A. et al. Patient-reported quality of life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy \u00b1 chemotherapy in the BC2001 phase III randomised controlled trial. Eur. Urol. 77, 260 (2020).","journal-title":"Eur. Urol."},{"key":"2568_CR28","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","volume":"27","author":"JA Efstathiou","year":"2009","unstructured":"Efstathiou, J. A. et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J. Clin. Oncol. 27, 4055\u20134061 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2568_CR29","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00345-020-03436-0","volume":"39","author":"VM Schuettfort","year":"2021","unstructured":"Schuettfort, V. M. et al. Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. World J. Urol. 39, 1757 (2021).","journal-title":"World J. Urol."},{"key":"2568_CR30","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky, M. D. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395, 1547\u20131557 (2020).","journal-title":"Lancet"},{"key":"2568_CR31","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 931\u2013945 (2021).","journal-title":"Lancet Oncol."},{"key":"2568_CR32","first-page":"S678","volume":"31","author":"MD Galsky","year":"2021","unstructured":"Galsky, M. D. et al. Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC). Ann. Oncol. 31, S678\u2013S724 (2021).","journal-title":"Ann. Oncol."},{"key":"2568_CR33","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383, 1218\u20131230 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2568_CR34","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.19.03091","volume":"38","author":"MD Galsky","year":"2020","unstructured":"Galsky, M. D. et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J. Clin. Oncol. 38, 1797\u20131806 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2568_CR35","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ijrobp.2014.01.001","volume":"88","author":"PJ Gray","year":"2014","unstructured":"Gray, P. J. et al. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int. J. Radiat. Oncol. Biol. Phys. 88, 1048\u201356 (2014).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2568_CR36","unstructured":"Becker, R. E. N. et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 79, 364\u2013371 (2020)."},{"key":"2568_CR37","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2568_CR38","doi-asserted-by":"publisher","unstructured":"Chalabi, M. et al. Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. Ann. Oncol. 33 https:\/\/doi.org\/10.1016\/j.annonc.2022.08.016 (2022).","DOI":"10.1016\/j.annonc.2022.08.016"},{"key":"2568_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.eururo.2022.07.023","volume":"83","author":"A Gil-Jimenez","year":"2023","unstructured":"Gil-Jimenez, A. et al. Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer. Eur. Urol. 83, 313\u2013317 (2023).","journal-title":"Eur. Urol."},{"key":"2568_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3390\/cancers11050639","volume":"11","author":"A Rossin","year":"2019","unstructured":"Rossin, A., Miloro, G. & Hueber, A. O. TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity. Cancers (Basel) 11, 639 (2019).","journal-title":"Cancers (Basel)"},{"key":"2568_CR41","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.xcrm.2022.100878","volume":"4","author":"MA Huseni","year":"2023","unstructured":"Huseni, M. A. et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep. Med. 4, 100878 (2023).","journal-title":"Cell Rep. Med."},{"key":"2568_CR42","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","volume":"83","author":"H-R Park","year":"2023","unstructured":"Park, H.-R. et al. Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma. Cancer Res. 83, 1968\u20131983 (2023).","journal-title":"Cancer Res."},{"key":"2568_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1037\/h0026256","volume":"70","author":"J Cohen","year":"1968","unstructured":"Cohen, J. Weighted kappa: nominal scale agreement provision for scaled disagreement or partial credit. Psychol. Bull. 70, 213\u2013220 (1968).","journal-title":"Psychol. Bull."},{"key":"2568_CR44","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483\u20131492 (2017).","journal-title":"Lancet Oncol."},{"key":"2568_CR45","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1158\/1078-0432.CCR-18-3388","volume":"25","author":"R Tokunaga","year":"2019","unstructured":"Tokunaga, R. et al. Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clin. Cancer Res. 25, 3096\u20133103 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2568_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405 (2015).","journal-title":"Genet. Med."},{"key":"2568_CR47","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","volume":"25","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin. Cancer Res. 25, 977\u2013988 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2568_CR48","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/cam4.1372","volume":"7","author":"A Vanderwalde","year":"2018","unstructured":"Vanderwalde, A., Spetzler, D., Xiao, N., Gatalica, Z. & Marshall, J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 7, 746\u2013756 (2018).","journal-title":"Cancer Med."},{"key":"2568_CR49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc."}],"updated-by":[{"DOI":"10.1038\/s41591-024-02814-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02568-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02568-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02568-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T17:30:00Z","timestamp":1730223000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02568-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2568"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02568-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-02814-0","URL":"https:\/\/doi.org\/10.1038\/s41591-024-02814-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D.G. has received research funding from Bristol Myers Squibb, Novartis, Dendreon, AstraZeneca, Merck and Genentech. He has served as a consultant to Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Pfizer, EMD Serono, SeaGen, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, Rappta Therapeutics, Alligator, Silverback, Fujifilm, Curis, Gilead, Bicycle, Asieris, Abbvie and Analog Devices. S.D. has served as a consultant to Janssen, Ferring, Photocure, Taris, Pacific Edge, QED, Abbvie, Janssen, Bristol Myers Squibb, Sesen, Protara, Pfizer and CG Oncology. T.B.D. has served as a consultant to Astellas, AstraZeneca, Bayer, Janssen and Sanofi. R.M. has served as a consultant to Bristol Myers Squibb, Roche, Astellas and Seattle Genetics and has received research funding from Merck and Astellas. C.K. has served as a consultant to Exelixis, Sanofi, AVEO, EMD Serono and Janssen and has received research funding from Sanofi, Gilead Sciences, AstraZeneca, ESSA Pharma, Pionyr and Incyte. He owns stock in Biogen and Epic Systems. T.J. is an employee of Genentech. A.H. has served as a consultant to HTG Molecular Diagnostics and Immunorizon. L.W. is an employee of GeneDx. K.W.M. has served as a consultant to EMD Serono, Pfizer, UroGen and Riva Therapeutics, has received research support from Pfizer and Novo Ventures, has equity in Riva Therapeutics, has received writing fees from UpToDate and has received speaking fees from OncLive. He is named on an institutional patent filed on mutational signatures of DNA repair deficiency. N.B. has served as a consultant to Apricity, BreakBio, Carisma Therapeutics, CureVac, Genetech, Novartis, Primevax, Tempest Therapeutics, Dragonfly Therapeutics, BioNTech, Genotwin and Rome Therapeutics. She has received research support from Harbour Biomed Sciences and Regeneron. J.Z. is an employee of GeneDx. S.G. received research funding from Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, Regeneron and Takeda. J.S. has served as a consultant or advisor for Natera, Pacific Edge, Merck, Urogen and Janssen. S.K.P. has received travel support form CRISPR Therapeutics and Ipsen. All remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}